UK - English
Select a Country

MEDIA ARCHIVE

The following information is intended as a resource for journalists only and was factualy correct at the time it was issued.

file


AbbVie's VIEKIRAX (ombitasvir/paritaprevir/ritonavir) and EXVIERA (dasabuvir) Licensed for Use in the UK for the treatment of Chronic Hepatitis C

19 January 2015

  • First treatment for chronic hepatitis C to combine three direct-acting antiviral agents to target hepatitis c virus (HCV) at multiple steps in the viral lifecycle
  • VIEKIRAX and EXVIERA, with or without ribavirin (RBV), cleared the virus in 97 percent of chronic genotype 1 (GT1) HCV patients and was generally well tolerated
  • AbbVie Care in hepatitis C also launched in the UK to help people maintain motivation, focus and stability while on treatment

 

Read full press release »


file


AbbVie is named “Company of the year 2014” at the Pharmaceutical Market Excellence Awards

17. November 2014

Read full press release »


file

AbbVie Announces Late-Breaking Results from Phase 3 Trial of HUMIRA® (adalimumab) in Hidradenitis Suppurativa (HS) Patients at the European Dermatology and Venereology Congress

11. October 2014

  • HS is a painful, chronic inflammatory skin disease that impacts approximately one to four percent of the adult population worldwide with no specific treatment options currently approved1,2,3 
  • Results show adalimumab meets primary endpoint in PIONEER II clinical trial
  • PIONEER II results, together with previously presented PIONEER I results, will contribute to worldwide regulatory filings for an expanded use of adalimumab

Read full press release »


file

Parents unaware of major health risk for babies

29. September 2014

Charities support campaign to raise awareness of bronchiolitis, the most common cause of infant hospital admissions in winter months

Read full press release »


file

AbbVie UK Launches New Campaign in Bath City Centre to Raise Awareness of Inflammatory Back Pain

September 15 2014

Acrobatic display brings to life the importance of a strong and healthy spine

Read full press release »


file

AbbVie Announces Pivotal Phase 3 Data Evaluating Efficacy of HUMIRA® (adalimumab) in Patients with Hidradenitis Suppurativa (HS), a Chronic Inflammatory Skin Disease

11. September 2014

  • Currently no approved treatment options available for patients living with HS, a skin disease which impacts approximately 1 percent of the adult population worldwide1,2
  • PIONEER I first Phase 3 trial to evaluate the investigational use of adalimumab in patients with moderate-to-severe HS3
  • Results show adalimumab meets primary endpoint3

Read full press release »


file

PsoriASSESS – New clinical, integrated psoriasis website for patients and doctors launched

2014

Website enables people with psoriasis to capture and share with their doctor their disease experience between consultations.

Read full press release »


file

PsoriASSESS: New online, integrated clinical psoriasis service/website for Dermatologists and patients launched

2014

Enables clinicians to monitor and better understand disease activity between consultations, improving communication between healthcare professionals and their patients.

Read full press release »


file

AbbVie UK Launches New Campaign in Reading to Raise Awareness of Inflammatory Back Pain

19 July 2014

Acrobatic display brings to life the importance of a strong and healthy spine

Read full press release »


file

Align: Large global study of patient attitudes shows link between improved adherence and anti-TNF therapy

11. June 2014

Patients across six chronic inflammatory diseases and 33 countries show positive association between adherence and anti-TNF therapy compared to conventional therapy.

Read full press release »


file

AbbVie to Present Late-Breaking Results from TURQUOISE-II Study in Chronic Hepatitis C Patients with Cirrhosis at the 2014 International Liver Congress™

April 2014

  • In patients with compensated liver cirrhosis and genotype 1 (GT1) chronic hepatitis C virus (HCV) infection, a difficult-to-treat population, TURQUOISE-II demonstrated SVR12 rates of 91.8 and 95.9 percent after 12 and 24 weeks of treatment, respectively
  • TURQUOISE-II is the largest phase III study of an all-oral, interferon-free treatment regimen conducted to date exclusively in GT1 HCV patients with cirrhosis
  • Results from TURQUOISE-II demonstrate high virologic response and similar tolerability profile as seen in GT1 patients in other AbbVie phase III studies
  • Results from TURQUOISE-II were published online today in The New England Journal of Medicine
  • AbbVie will also present detailed data from the phase II M12-999 study and phase III PEARL-III study

Read full press release »


file

AbbVie to Present Detailed Phase III Results from SAPPHIRE-I and SAPPHIRE-II Studies in Chronic Hepatitis C Patients at the 2014 International Liver Congress™

April 2014

  • SVR12 rates of 96 percent were achieved in both SAPPHIRE-I (new to therapy) and SAPPHIRE-II (treatment-experienced with pegylated interferon and ribavirin) in adult patients with genotype 1 chronic hepatitis C virus infection
  • All treatment-experienced sub-populations in the SAPPHIRE-II study achieved SVR12 rates of 95-100 percent
  • SAPPHIRE-I and SAPPHIRE-II results were published online in The New England Journal of Medicine

Read full press release »


file

Maidenhead MP Theresa May visits AbbVie to recognise first year as independent biopharmaceutical company

7. February 2014

Read full press release »


file

AbbVie Completes Largest Phase III Program of an All-Oral, Interferon-Free Therapy for the Treatment of Hepatitis C Genotype 1

January 2014

  • Ninety-nine percent SVR12 rates with and without ribavirin in certain patient types
  • Even in difficult-to-treat patients (cirrhotic patients) achieved 92-96 percent SVR12 rates
  • AbbVie expects U.S. launch in 2014

Read full press release » 


file

AbbVie Demonstrates 96 percent SVR 12 in its Phase III Study of Treatment- Experienced Patients with Genotype 1 Hepatitis C

December 2013

  • Results further confirm phase II studies, with consistent virologic response and tolerability profile
  • SAPPHIRE-II is the second of six phase III trials studying the investigational 3D regimen
  • Future data anticipated from AbbVie’s clinical trials examines 3D regimen with and without ribavirin, as well as treatment of hepatitis C in patients with cirrhosis

Read full press release »


file

AbbVie Releases First of Six Phase III Results from Investigational All-Oral, Interferon-Free, 12-week Regimen, Showing 96 Percent SVR12 in Genotype 1 Hepatitis C Patients New to Therapy 

November 2013

  • Confirms results of phase II studies, with consistent virologic response and tolerability profile
  • Largest all-oral, interferon-free clinical program in genotype 1 (GT1) patients to date1
  • On track for major regulatory submissions in Q2 2014
  • Worldwide, about 160 million people are chronically infected with hepatitis C2

Read full press release »


file

AbbVie announces new analysis evaluating early response of Humira® (Adalimumab) treatment in paediatric patients with moderately to severely active Crohn’s disease

November 2013

  • Post-hoc analysis of the Phase 3 IMAgINE-1 trial suggested HUMIRA may induce clinical remission and response at week 4

Read full press release »


file

World Prematurity Day 2013

December 2013

Parents unaware of the threat of winter illnesses to their newborn baby, new research finds.

Read full press release »


file

All Wales medicines strategy group (AWMSG) recommends Humira (Adalimumab) for use within NHS Wales to treat under-recognised chronic disease associated with inflammatory back pain

August 2013

Read full press release »


file

Humira® (Adalimumab) accepted for use within NHS Scotland by the Scottish medicines

July 2013

HUMIRA® (adalimumab) ACCEPTED FOR USE WITHIN NHS SCOTLAND BY THE SCOTTISH MEDICINES CONSORTIUM (SMC) TO TREAT PAEDIATRIC CROHN’S DISEASE 

Read full press release »


file

Global survey of rheumatoid arthritis (RA) patients shows patients’ perception of their RA disease management is lowest in the UK

June 2013

  • Almost two thirds of UK rheumatoid arthritis (RA) patients do not feel their RA is well managed
  • Just over a quarter of UK RA patients say they have a disease management plan in place, compared to 56% globally
  • Global survey prompts calls for increased collaboration between doctors and patients

Read full press release »


Leave the UK site

The Abbvie Internet site that you have requested is intended for the residents of a particular country or countries, as noted on that site. As a result, the site may contain information on pharmaceuticals and other products or uses of those products that are not approved in other countries or regions. If you are a resident of a country other than those to which the site is directed, please contact your local AbbVie affiliate to obtain the appropriate product information for your country of residence.

The Abbvie Internet site that you have requested may be in a language that differs from your country of origin.

The Abbvie Internet site that you have requested may not be optimised for your screen size.

Do you wish to continue to this Abbvie site?

Exit abbvie.co.uk

The product-specific Internet site that you have requested is intended for the residents of a particular country or countries, as noted on that site. As a result, the site may contain information on pharmaceuticals and other products or uses of those products that are not approved in other countries or regions. If you are a resident of a country other than those to which the site is directed, please return to AbbVie.com or contact your local AbbVie affiliate to obtain the appropriate product information for your country of residence.

The product-specific Internet site that you have requested may not be optimized for your screen size.

Do you wish to continue to this product-specific site?

AXCOR121934c(2) - DECEMBER 2014

Exit abbvie.co.uk

Notice

The “Yes” link below will take you out of AbbVie family of websites

Links which take you out of AbbVie worldwide web sites are not under the control of AbbVie, and AbbVie are not responsible for the contents of any such site or any further links from such site. AbbVie is providing these links to you only as a convenience and the inclusion of any link does not imply endorsement of the linked site by AbbVie.

The Internet site that you have requested may not be optimized to your screen size.

Do you wish to leave this site?